UROKINASE-TYPE PLASMINOGEN ACTIVATOR AND INHIBITOR AS PROGNOSTIC MARKERS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND LYMPH NODE METASTASES

被引：0
作者：
Lumachi, F. [1 ]
Marino, F. [2 ]
Santeufemia, D. A. [3 ]
Chiara, G. B. [3 ]
Basso, S. M. [3 ]
机构：
[1] Univ Padua, Sch Med, Dept Surg & Gastroenterol Sci, Padua, Italy
[2] Univ Padua, Dept Pathol, Sch Med, I-35100 Padua, Italy
[3] S Maria Angeli Hosp, Pordenone, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S41 / S41
页数：1
相关论文
共 50 条
[31]   Lymph node ratio is a prognostic factor for non-small cell lung cancer [J].
Sun, Guangyuan ;
Xue, Lei ;
Wang, Mingdong ;
Zhao, Xuewei .
ONCOTARGET, 2015, 6 (32) :33912-33918
[32]   Lymph node metastases in clinically node negative peripheral non-small cell lung cancer [J].
Mehmood, T. .
ANNALS OF ONCOLOGY, 2017, 28
[33]   Prognostic value of urokinase plasminogen activator system in non-small cell lung cancer: A systematic review and meta-analysis [J].
Lu, Jia-Ju ;
Guo, Hong ;
Gao, Bo ;
Zhang, Yun ;
Lin, Qing-Ling ;
Shi, Jiang ;
Liu, Jing-Jing ;
Liu, Jian .
MOLECULAR AND CLINICAL ONCOLOGY, 2018, 8 (01) :127-132
[34]   Is the urokinase-type plasminogen activator system a reliable prognostic factor in gastric cancer? [J].
Luebke, T. ;
Baldus, S. E. ;
Spieker, D. ;
Grass, G. ;
Bolischweiler, E. ;
Schneider, P. M. ;
Thiele, J. ;
Dienes, H. P. ;
Hoelscher, A. H. ;
Monig, S. P. .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2006, 21 (03) :162-169
[35]   The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer [J].
Banys-Paluchowski, Malgorzata ;
Witzel, Isabell ;
Aktas, Bahriye ;
Fasching, Peter A. ;
Hartkopf, Andreas ;
Janni, Wolfgang ;
Kasimir-Bauer, Sabine ;
Pantel, Klaus ;
Schoen, Gerhard ;
Rack, Brigitte ;
Riethdorf, Sabine ;
Solomayer, Erich-Franz ;
Fehm, Tanja ;
Mueller, Volkmar .
SCIENTIFIC REPORTS, 2019, 9 (1)
[36]   The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer [J].
Malgorzata Banys-Paluchowski ;
Isabell Witzel ;
Bahriye Aktas ;
Peter A. Fasching ;
Andreas Hartkopf ;
Wolfgang Janni ;
Sabine Kasimir-Bauer ;
Klaus Pantel ;
Gerhard Schön ;
Brigitte Rack ;
Sabine Riethdorf ;
Erich-Franz Solomayer ;
Tanja Fehm ;
Volkmar Müller .
Scientific Reports, 9
[37]   Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: Correlation with tumor associated macrophage and prognosis [J].
Ohba, K ;
Miyata, Y ;
Kanda, S ;
Koga, S ;
Hayashi, T ;
Kanetake, H .
JOURNAL OF UROLOGY, 2005, 174 (02) :461-465
[38]   Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease [J].
Qin, WY ;
Zhu, WZ ;
Wagner-Mann, C ;
Sauter, ER .
ANNALS OF SURGICAL ONCOLOGY, 2003, 10 (08) :948-953
[39]   Nipple Aspirate Fluid Expression of Urokinase-Type Plasminogen Activator, Plasminogen Activator Inhibitor-1, and Urokinase-Type Plasminogen Activator Receptor Predicts Breast Cancer Diagnosis and Advanced Disease [J].
Wenyi Qin ;
Weizhu Zhu ;
Colette Wagner-Mann ;
Edward R. Sauter .
Annals of Surgical Oncology, 2003, 10 :948-953
[40]   Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: Analysis of their prognostic significance in squamous cell carcinoma of the head and neck [J].
Strojan, P ;
Budihna, M ;
Smid, L ;
Vrhovec, I ;
Skrk, J .
ANTICANCER RESEARCH, 2000, 20 (5C) :3975-3981
12345